Chemed (CHE) Stock Price, News & Analysis

Company Overview

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings. Its services include medical care, pain and symptom management, nursing, counseling, social services and support for patients’ families.

Roto-Rooter provides plumbing and drain-cleaning services for residential, commercial and institutional customers. Its offerings include emergency plumbing repair, sewer and drain cleaning, water damage cleanup and related restoration services. Chemed has owned Roto-Rooter since 1980 and acquired VITAS Healthcare in 2004. Kevin J. McNamara serves as Chemed’s president and chief executive officer.

Key Stats

• Today's Range: $506.26 to $516.78
• 50-Day Range: $495.57 to $548.27
• 52-Week Range: $365.20 to $557.00
• Volume: 115,689 shs
• Average Volume: 142,063 shs
• Market Capitalization: $6.67 billion
• P/E Ratio: 25.64
• Dividend Yield: 0.55%
• Price Target: $554.60
• Consensus Rating: Hold

Chemed Stock Analysis - MarketRank™

Chemed scored higher than 90% of companies evaluated by MarketBeat, and ranked 40th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Hold

Consensus Rating

Chemed has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 2 buy ratings, 5 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Chemed is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Chemed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 6.88%

Earnings Growth

Earnings for Chemed are expected to grow by 6.88% in the coming year, from $23.55 to $25.17 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chemed is 25.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 36.57.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chemed is 25.64, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 215.25.

Price to Earnings Growth Ratio

Chemed has a PEG Ratio of 2.07. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Chemed has a P/B Ratio of 7.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.72% of the float of Chemed has been sold short.

Short Interest Ratio / Days to Cover

Chemed has a short interest ratio ("days to cover") of 3.28, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chemed has recently decreased by 8.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Chemed has a dividend yield of 0.55%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Chemed has been increasing its dividend for 16 years.

Dividend Coverage

The dividend payout ratio of Chemed is 14.06%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Chemed will have a dividend payout ratio of 11.12% next year. This indicates that Chemed will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.74

News Sentiment

Chemed has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Chemed this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for CHE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Chemed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Chemed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,833,160.00 in company stock.

Percentage Held by Insiders

3.33% of the stock of Chemed is held by insiders.

Percentage Held by Institutions

95.85% of the stock of Chemed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/28/2026
• Record date for 9/3 Dividend: 8/17/2026
• Ex-Dividend for 9/3 Dividend: 8/17/2026
• Dividend Payable: 9/03/2026
• Today: 10/22/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NYSE:CHE
• CIK: 19584
• Web: www.chemed.com
• Phone: (513) 762-6690
• Fax: 513-762-6590
• Employees: 15,811
• Year Founded: 1970

Price Target and Rating

• Average Price Target for Chemed: $554.60
• High Price Target: $650.00
• Low Price Target: $475.00
• Potential Upside/Downside: +8.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $19.91
• Trailing P/E Ratio: 25.64
• Forward P/E Ratio: 21.68
• P/E Growth: 2.07
• Net Income: $265.24 million
• Net Margins: 10.60%
• Pretax Margin: 14.23%
• Return on Equity: 31.77%
• Return on Assets: 18.90%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 0.91
• Quick Ratio: 0.89

Sales & Book Value

• Annual Sales: $2.60 billion
• Price / Sales: 2.57
• Cash Flow: $24.40 per share
• Price / Cash Flow: 20.92
• Book Value: $69.15 per share
• Price / Book: 7.38

Miscellaneous

• Outstanding Shares: 13,070,000
• Free Float: 12,635,000
• Market Cap: $6.67 billion
• Optionable: Optionable
• Beta: 0.51